Alzecure: Receives Approval to Start ACD856 Phase I “MAD” Study

We give a brief comment on today's news that Alzecure has recieved approval to start the "MAD"-part of its phase 1 study for ACD856.


Fredrik Thor

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.